ArticleCancers2020
Economic Evaluation of Population-Based
Abstract read
In one paragraph
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The Cost Effectiveness of Genomic Medicine in Cancer Control: A Systematic Literature Review.Applied health economics and health policy · 2025Pooled it
- Economic evaluation of germline genetic testing for breast cancer in low- and middle-income countries: a systematic review.BMC cancer · 2024Pooled it
- Direct Medical Costs, Productivity Loss Costs and Out-Of-Pocket Expenditures in Women with Breast Cancer in Latin America and the Caribbean: A Systematic Review.PharmacoEconomics · 2021Pooled it
- Limited inclusion in clinical trials and access to poly (ADP-ribose) polymerase inhibitors in racial and ethnic minority patients with cancer: a narrative review.The oncologist · 2026Review
- Towards a Multi-sectoral Approach to Population Health: A Scoping Review of Cross-sectoral Evaluations of Health Interventions.Applied health economics and health policy · 2026Review
- Psychologically informed reminder messages for promoting BRCA1/2 carrier screening: evidence from a large-scale population-based study.European journal of public health · 2026Observational
- Cost-effectiveness and budget impact of breast cancer genetic profiling in Egypt.Ecancermedicalscience · 2026Review
- Feasibility and outcomes of the DNA Screen nationwide adult genomic screening pilot.Nature health · 2026Article
- Cost-effectiveness of genetic risk-stratified screening for breast cancer in Taiwan.Breast (Edinburgh, Scotland) · 2025Article
- 17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing?ESMO gastrointestinal oncology · 2025Article
- Economic evaluation of personalised versus conventional risk assessment for women who have undergone testing for hereditary breast and ovarian cancer genes: a modelling study.Journal of medical genetics · 2025Article
- Cost-effectiveness analysis of population-basedFrontiers in public health · 2025Article
- Reduced Breast and Ovarian Cancer Through Targeted Genetic Testing: Estimates Using the NEEMO Microsimulation Model.Cancers · 2024Article
- Economic Evaluation of Population-Based BRCA1 and BRCA2 Testing in Canada.JAMA network open · 2024Article
- Exploring Therapeutic Challenges in Patients with HER2-Positive Breast Cancer-A Single-Center Experience.Life (Basel, Switzerland) · 2024Article
- Evaluation of an Italian Population-Based Programme for Risk Assessment and Genetic Counselling and Testing for BRCA1/2-Related Hereditary Breast and Ovarian Cancer after 10 Years of Operation: An Observational Study Protocol.Methods and protocols · 2024Article
- Article
- Screening and prevention of ovarian cancer.The Medical journal of Australia · 2024Review
- Article
- Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.JAMA network open · 2024Article
Corrections and comments
- Commented on by
Authors and funding
18 authors.
Ranjit ManchandaWolfson Institute for Preventive Medicine, CRUK Barts Cancer Centre, Queen Mary University of London, London EC1M 6BQ, UK.ORCID 0000-0003-3381-5057
Li SunWolfson Institute for Preventive Medicine, CRUK Barts Cancer Centre, Queen Mary University of London, London EC1M 6BQ, UK.ORCID 0000-0001-5569-7296
Shreeya PatelWolfson Institute for Preventive Medicine, CRUK Barts Cancer Centre, Queen Mary University of London, London EC1M 6BQ, UK.
Olivia EvansWolfson Institute for Preventive Medicine, CRUK Barts Cancer Centre, Queen Mary University of London, London EC1M 6BQ, UK.
Janneke WilschutDepartment of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, Netherlands.ORCID 0000-0002-4921-227X
Ana Carolina De Freitas LopesDepartamento de Medicina Preventiva, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, 01246903 Sao Paulo, Brazil.
Faiza GabaWolfson Institute for Preventive Medicine, CRUK Barts Cancer Centre, Queen Mary University of London, London EC1M 6BQ, UK.
Adam BrentnallCentre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London EC1M 6BQ, UK.ORCID 0000-0001-6327-4357
Stephen DuffyCentre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London EC1M 6BQ, UK.
Bin CuiSchool of Public Health, Peking University, Beijing 100191, China.
Patricia Coelho De SoarezDepartamento de Medicina Preventiva, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, 01246903 Sao Paulo, Brazil.ORCID 0000-0001-8383-0728
Zakir HusainDepartment of Humanities & Social Sciences, Indian Institute of Technology, Kharagpur, West Bengal 721302, India.
John HopperCentre for Epidemiology & Biostatistics, Melbourne School of Population & Global Health, Faculty of Medicine, Dentistry & Health Sciences, University of Melbourne, Victoria 3010, Australia.
Zia SadiqueDepartment of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London WC1H 9SH, UK.
Asima MukhopadhyayTata Medical Centre, Kolkata, West Bengal 700160, India.
Li YangSchool of Public Health, Peking University, Beijing 100191, China.
Johannes BerkhofDepartment of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, Netherlands.
Rosa LegoodDepartment of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London WC1H 9SH, UK.
Funding
Cancer Research UK C569/A16891Eve Appeal EMSG1K9R
Abstract
Clinical criteria/Family history-based
Indexed as
BRCAbreast cancercancer preventioncost-effectivenessovarian cancerpopulation testing
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.